Skip to main content
SpringerLink
Log in

Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Recommended guidelines have limited breast cancer gene (BRCA1) mutation testing to individuals with a personal or family history of early onset breast and/or ovarian cancer, and those with multiple affected close relatives. Such large breast cancer families are rare in the general population, limiting the clinical application of the BRCA1 discovery. Previous reports have suggested an association between medullary breast cancer and BRCA1 mutation carriers. To test the feasibility of using these rare histological subtypes as an alternative to epidemiological factors, 42 cases of medullary cancer unselected for family history were screened for BRCA1 point mutations and large exon rearrangements. The large majority (83%) of these patients did not have significant family of breast or ovarian cancer. Two deleterious mutations resulting in a premature stop codon, and one exon 13 duplication were found. All mutations were detected in patients with typical medullary cancer, who had family history of multiple breast and ovarian cancers. Our findings suggest that medullary breast cancers are not an indication for BRCA1 mutation screening in the absence of significant family risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56: 265–271, 1995

    Google Scholar 

  2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield LA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: 676–689, 1998

    Google Scholar 

  3. Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, Lynch HT, Feunteun J, Lenoir GM: A high incidence of BRCA1 mutations in breast-ovarian cancer families. Am J Hum Genet 58: 42–51, 1996

    Google Scholar 

  4. Claus EB, Risch N, ThompsonWD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48: 232–242, 1991

    Google Scholar 

  5. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualised probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879–1886, 1989

    Google Scholar 

  6. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V: Medullary carcinoma of the breast: a clinicopathological study with 10 year follow-up. Cancer 40: 1365–1385, 1977

    Google Scholar 

  7. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW: Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20: 479–489, 1992

    Google Scholar 

  8. Sng JH, Chang J, Feroze F, Rahman N, Tan W, Lim S, Lehnert M, van der Pool S, Wong J: The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 82: 538–542, 2000

    Google Scholar 

  9. Plummer SJ, Anton-Culvar H, Webster L, Noble B, Liao S, Kennedy A, Berlinson J, Casey G: Detection of BRCA1 mutation by the protein truncation test. Hum Mol Genet 12: 1989–1991, 1995

    Google Scholar 

  10. Hogervorst FBL, Cornelis RS, Bout M, van Vliet M, Ooterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Meijers-Heijboer H, Menko FH, Cornelisse CJ, den Dunnen JT, Devilee P, van Ommen G-JB: Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10: 208–212, 1996

    Google Scholar 

  11. Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67: 841–850, 2000

    Google Scholar 

  12. Payne SR, Newman B, King MC: Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer. Genes Chromosome Cancer 29(1): 58–62, 2000

    Google Scholar 

  13. Chang J, Elledge RM: Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 69: 101–113, 2001

    Google Scholar 

  14. Kaufman DJ, Struewing JP: Re: effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 91: 1250–1251, 1999

    Google Scholar 

  15. American Society of Clinical Oncology, Statement of the American Society of Clinical Onclogy: genetic testing for cancer susceptibility. J Clin Oncol 14: 1730–1736, 1996

    Google Scholar 

  16. Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P, Kuttenn F, Lebrun JP, Lefranc JP, Pierret J, Sobol H, Stoppa-Lyonnet D, Thouvenin D, Tristant H, Feingold J: Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 9: 939–950, 1998

    Google Scholar 

  17. Pharoah PD, Stratton JF, Mackay J: Screening for breast and ovarian cancer: the relevance of family history. Br Med Bull 54: 823–838, 1998

    Google Scholar 

  18. Iau PTC, Marafie M, Macmillian D, Wenzyck P, Kollias J, Cross G, Scott N, Blamey RW: Prevalence of BRCA1 and BRCA2 mutations in a breast cancer family history clinic. Breast 8: 218, 1999.

    Google Scholar 

  19. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: pathology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 77: 697–709, 1996

    Google Scholar 

  20. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Sorfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Orniston W, McManus R, Schemeck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90: 1138–1145, 1998

    Google Scholar 

  21. Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP: HER-2/neu status and tumour morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 95: 2068–2075, 2002

    Google Scholar 

  22. Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BA, Friedman LS: Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosome Cancer 25: 91–96, 1999

    Google Scholar 

  23. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancer in carriers of BRCA1 and BRCA2 and sporadic cases. Lancet 349: 1505–1510, 1997

    Google Scholar 

  24. Armes J, Matthew Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ: The histological phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations. Cancer 83: 2335–2345, 1998

    Google Scholar 

  25. Eisinger F, Soppa-Lyonnet, Longy M, Kerangueven F, Noguchi T, Bailly C, Vinson-Salomon A, Jacquemier J, Birnbaum D, Sobol H: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56: 471–474, 1996

    Google Scholar 

  26. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat J, Longy M, Guinebretiere JM, Sauvan R, Noguchi T, Birnbaum D, Sobol H: Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58: 1588–1592, 1998

    Google Scholar 

  27. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642–1649, 1998

    Google Scholar 

  28. Verhoog LC, Brekelmans CTM, Seynaeve C, van den Bosch LMC, Dahmen G, van Geel AN, Bartels CC, Tilanus-Lindhorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG: Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351: 316–321, 1998

    Google Scholar 

  29. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16: 397–404, 1998

    Google Scholar 

  30. Pederson L, Holck S, Schiodt T, Zedeler K, Mouridsen HT: Inter-and intra-observer variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications. Breast Cancer Res Treat 14: 97–99, 1989

    Google Scholar 

  31. Pederson L, Zedeler K, Holck S, Shiodt T, Mouridsen HT: Medullary carcinoma of the breast, proposal for a simplified histopathological definition. Br J Cancer 63: 591–595, 1991

    Google Scholar 

  32. Rigaud C, Theobald S, Noel P, Badreddine J, Barlier C, Delobelle A, Gentile A, Jacquemier J, Maisongrosse V, Peffault de Latour M, Trojani M, Zafrani B: Medullary cancer of the breast: a multicentre study of its diagnostic consistency. Arch Pathol Lab Med 117: 1005–1008, 1993

    Google Scholar 

  33. Anderson DE: Genetic study of breast cancer: identification of a high-risk group. Cancer 34: 1090–1097, 1974

    Google Scholar 

  34. Rosen PP, Lesser ML, Senie MA, Kinne DW: Epidemiology of breast carcinoma III: relationship of family history to tumour type. Cancer 50: 171–179, 1982

    Google Scholar 

  35. Puget N, Torchard D, Serova-Sininikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S: A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 57: 828–831, 1997

    Google Scholar 

  36. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk L, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJ, Devilee P: BRCA1 genomic deletions are major founder effects in Dutch breast cancer patients. Nat Genet 7: 341–345, 1997

    Google Scholar 

  37. Rohlfs EM, Puget N, Graham ML, Weber BL, Garber JE, Skrzynia C, Helperin GJ, Lenoir GM, Silverman LM, Mazoyer S: An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosome Cancer 28: 300–307, 2000

    Google Scholar 

  38. The Exon 13 Duplication Screening Group: The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 67: 207–212, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, National University Hospital, Singapore

    P.T.C. Iau, A. Ali & J.H. Sng

  2. Centre For Medical Genetics, Safat Postal Code, Kuwait

    M. Marafie

  3. Professorial Unit of Surgery, City Hospital, Hucknall Road, Nottingham, UK

    R.D. Macmillan, P. Wenzyck, N. Scott & R.W. Blamey

  4. Department of Pathology, City Hospital, Hucknall Road, Nottingham, UK

    S. Pinder, H.E. Denley & I.O. Ellis

  5. Department of Molecular Genetics, City Hospital, Hucknall Road, Nottingham, UK

    G. Cross

Authors
  1. P.T.C. Iau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Marafie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.H. Sng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R.D. Macmillan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Pinder
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H.E. Denley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I.O. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Wenzyck
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Cross
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R.W. Blamey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iau, P., Marafie, M., Ali, A. et al. Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer. Breast Cancer Res Treat 85, 81–88 (2004). https://doi.org/10.1023/B:BREA.0000021049.61839.e5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000021049.61839.e5

Search

Navigation